Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171955 | 0.84 | PDE4B (0.49) | PDE4BPDE3A | |
| SCHEMBL2171217 | 0.82 | GRM5 (0.45) | PDE4BPDE3APDE5A | |
| SCHEMBL2174131 | 0.82 | PDE4B (0.46) | PDE4BPDE3APDE5A | |
| SCHEMBL12436123 | 0.78 | PDE4B (0.51) | PDE4BPDE3A | |
| SCHEMBL2215867 | 0.77 | PDE4B (0.47) | PDE4BPDE3APDE5AHDAC6 | |
| SCHEMBL12436121 | 0.75 | PDE4B (0.52) | PDE4BPDE3A | |
| SCHEMBL2171205 | 0.75 | PDE4B (0.54) | PDE4BPDE3A | |
| SCHEMBL2170938 | 0.74 | PDE4B (0.52) | PDE4BPDE3A | |
| SCHEMBL2170456 | 0.74 | PDE4B (0.50) | PDE4BPDE3A | |
| SCHEMBL2170154 | 0.73 | PDE4B (0.52) | PDE4BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035745-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PDE4B 6/4885PDE3A 1/4885PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.